TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06787950: A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Anti-tumor Activity of ASN-3186 in Patients with Advanced Solid Tumors.

Sponsor: Jiangsu Yahong Meditech Co., Ltd aka Asieris · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 200 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT06787950 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06787950 Rescue Dossier →